Cytori (CYTX) Publishes Apollo (P1/2a Heart Attack) Data
Cytori – (CYTX): Publishes Appolo Results
Cytori Therapeutics (NASDAQ: CYTX) published previously reported six-month outcomes from their Apollo trial. This was an EU trial evaluating adipose (fat) derived stem cells (ADCs) in patients with acute myocardial infarction (heart attack or AMI).
Apollo was small at N=14-patients but it was a prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA).
In the Apollo trial all patients were treated with standard-of-care and subsequently underwent an abdominal liposuction. Each patient's adipose tissue was processed by the Celution® System where ADRCs were extracted, washed and concentrated into a syringe of clinical grade cells. Within 36 hours of the myocardial infarction and no longer than 24 hours after undergoing percutaneous coronary intervention, patients received an injection of either 20 million ADRCs (n=10) or a placebo (n=4). Improvement in cardiac function by SPECT and an improvement in blood flow as well as a reduction in scar formation (infarct size).
Cytori claims that the “advantage of adipose tissue as a cell source is that it allows physicians to get a meaningful dose of a patient's own cells at the point-of-care when using the Celution® System without cell culture or use of donor cells". The paper’s author also states, "We believe delivering cells within the first 24 to 36 hours takes advantage of the body's signaling and initiates the repair process before irreparable damage occurs".
cytori, cytx | Print Article Email Article Posted on Tuesday, January 24, 2012 at 3:56PM Permalink in Regenerative Medicine
Reader Comments